Loading
Giving four doses of cemiplimab before surgery for resectable cutaneous squamous cell carcinoma eliminated all viable tumour in half of patients and left only minimal residual disease in another 13 percent, opening the way to smaller operations and less radiotherapy.
Phase 2 study of 79 patients with resectable stage II to IV (M0) cutaneous squamous cell carcinoma treated with up to four doses of neoadjuvant cemiplimab followed by surgery.
Pathological complete response was 50.6 percent and major pathological response (10 percent or less viable tumour) a further 12.7 percent; radiological response underestimated pathological response, and adverse events were consistent with PD-1 blockade.
Neoadjuvant cemiplimab is now used to shrink large or function-threatening cutaneous squamous cell carcinomas before surgery, and pathological response is being studied as a guide to omitting adjuvant radiotherapy.
Shares Advanced cutaneous squamous cell carcinoma, Cemiplimab, New England Journal of Medicine.
Shares Advanced cutaneous squamous cell carcinoma, Cemiplimab, New England Journal of Medicine.
Shares Advanced cutaneous squamous cell carcinoma, Cemiplimab.
Shares Advanced cutaneous squamous cell carcinoma, Cemiplimab.
Shares Advanced cutaneous squamous cell carcinoma, Cemiplimab.
Shares Neoadjuvant cemiplimab for resectable stage II to IV skin squamous cell carcinoma, Advanced cutaneous squamous cell carcinoma.
Shares Neoadjuvant cemiplimab for resectable stage II to IV skin squamous cell carcinoma, Advanced cutaneous squamous cell carcinoma, Cemiplimab.